163 related articles for article (PubMed ID: 28487299)
1. The first reported case of Atypical Femoral Fracture caused by daily ibandronate prescribed for bone metastases in breast cancer.
Espey R; Grimes S; Heyburn G; Kealey WD
BMJ Case Rep; 2017 May; 2017():. PubMed ID: 28487299
[TBL] [Abstract][Full Text] [Related]
2. Bisphosphonate-related atypical femoral fracture with bone metastasis of breast cancer: case report and review.
Hayashi K; Aono M; Shintani K; Kazuki K
Anticancer Res; 2014 Mar; 34(3):1245-9. PubMed ID: 24596367
[TBL] [Abstract][Full Text] [Related]
3. Atypical femur fractures among breast cancer and multiple myeloma patients receiving intravenous bisphosphonate therapy.
Chang ST; Tenforde AS; Grimsrud CD; O'Ryan FS; Gonzalez JR; Baer DM; Chandra M; Lo JC
Bone; 2012 Sep; 51(3):524-7. PubMed ID: 22634175
[TBL] [Abstract][Full Text] [Related]
4. A case of femoral diaphyseal fracture after long-term treatment with zoledronic acid.
Ishizuna K; Ota D; Fukuuchi A; Teraoka M; Fujii A; Mori M; Nishi T
Breast Cancer; 2015 Jan; 22(1):90-4. PubMed ID: 22009549
[TBL] [Abstract][Full Text] [Related]
5. Bilateral atypical femur fractures without bisphosphonate exposure.
Szolomayer LK; Ibe IK; Lindskog DM
Skeletal Radiol; 2017 Feb; 46(2):241-247. PubMed ID: 27900455
[TBL] [Abstract][Full Text] [Related]
6. The limitations of today's clinical guidance: Atypical femoral fracture and long-term bone-modifying agents in the oncology setting.
Cheung E; Borno HT
J Oncol Pharm Pract; 2020 Jul; 26(5):1180-1189. PubMed ID: 32122232
[TBL] [Abstract][Full Text] [Related]
7. [Atypical femoral fracture associated with the use of bisphosphonates, an adverse drug reaction not to be missed].
Ing Lorenzinit K; Meier R; Suva D; Dayer P; Desmeules J; Peter R
Rev Med Suisse; 2012 Jun; 8(344):1238-42. PubMed ID: 22730621
[TBL] [Abstract][Full Text] [Related]
8. Bone pain reduction in patients with metastatic breast cancer treated with ibandronate-results from a post-marketing surveillance study.
Diel IJ; Kurth AH; Sittig HB; Meden H; Maasberg M; Sandermann A; Bergner R
Support Care Cancer; 2010 Oct; 18(10):1305-12. PubMed ID: 20151162
[TBL] [Abstract][Full Text] [Related]
9. Rare non-traumatic periprosthetic femoral fracture with features of an atypical femoral fracture: a case report.
Niikura T; Lee SY; Sakai Y; Kuroda R; Kurosaka M
J Med Case Rep; 2015 May; 9():103. PubMed ID: 25943378
[TBL] [Abstract][Full Text] [Related]
10. Impending Atypical Femoral Fracture in Patients With Medullary Thyroid Cancer With Skeletal Metastasis Treated With Long-term Bisphosphonate and Denosumab.
Koizumi M; Gokita T; Toda K
Clin Nucl Med; 2017 Jun; 42(6):463-464. PubMed ID: 28240655
[TBL] [Abstract][Full Text] [Related]
11. Bilateral simultaneous femoral diaphyseal fractures in a patient with long-term ibandronate use.
Patel VC; Lazzarini AM
Orthopedics; 2010 Oct; 33(10):775. PubMed ID: 20954650
[TBL] [Abstract][Full Text] [Related]
12. Loading dose ibandronate versus standard oral ibandronate in patients with bone metastases from breast cancer.
Macpherson IR; Bray C; Hopkins C; Hannon RA; Lewsley LA; Ritchie DM; Canney P
Clin Breast Cancer; 2015 Apr; 15(2):117-27. PubMed ID: 25454689
[TBL] [Abstract][Full Text] [Related]
13. Impending Atypical Femoral Fracture in a Patient of Breast Cancer With Bone Metastases Receiving Long-term Denosumab.
Sugihara T; Koizumi M; Hayakawa K; Ito Y; Sata N
Clin Nucl Med; 2018 May; 43(5):365-366. PubMed ID: 29517548
[TBL] [Abstract][Full Text] [Related]
14. Risk Factors for Developing Skeletal-Related Events in Breast Cancer Patients With Bone Metastases Undergoing Treatment With Bone-Modifying Agents.
Tanaka R; Yonemori K; Hirakawa A; Kinoshita F; Takahashi N; Hashimoto J; Kodaira M; Yamamoto H; Yunokawa M; Shimizu C; Fujimoto M; Fujiwara Y; Tamura K
Oncologist; 2016 Apr; 21(4):508-13. PubMed ID: 26975863
[TBL] [Abstract][Full Text] [Related]
15. Oral ibandronate in metastatic bone breast cancer: the Florence University experience and a review of the literature.
Meattini I; Bruni A; Scotti V; Livi L; De Luca Cardillo C; Galardi A; Cipressi S; Biti G
J Chemother; 2010 Feb; 22(1):58-62. PubMed ID: 20227995
[TBL] [Abstract][Full Text] [Related]
16. Surgical Management of Atypical Femur Fractures Associated With Bisphosphonate Therapy.
Githens M; Garner MR; Firoozabadi R
J Am Acad Orthop Surg; 2018 Dec; 26(24):864-871. PubMed ID: 30256339
[TBL] [Abstract][Full Text] [Related]
17. Atypical tibial fracture in breast cancer patient with bone metastasis receiving denosumab therapy: a case report and review of the literature.
Yanagisawa Y; Suzuki H; Gamada H; Yamazaki M
J Med Case Rep; 2023 Jun; 17(1):257. PubMed ID: 37340320
[TBL] [Abstract][Full Text] [Related]
18. Long-term safety of intravenous ibandronic acid for up to 4 years in metastatic breast cancer: an open-label trial.
Pecherstorfer M; Rivkin S; Body JJ; Diel I; Bergström B
Clin Drug Investig; 2006; 26(6):315-22. PubMed ID: 17163265
[TBL] [Abstract][Full Text] [Related]
19. A Phase II trial evaluating the palliative benefit of second-line oral ibandronate in breast cancer patients with either a skeletal related event (SRE) or progressive bone metastases (BM) despite standard bisphosphonate (BP) therapy.
Clemons M; Dranitsaris G; Ooi W; Cole DE
Breast Cancer Res Treat; 2008 Mar; 108(1):79-85. PubMed ID: 17473981
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of oral ibandronate versus IV zoledronic acid or IV pamidronate for bone metastases in patients receiving oral hormonal therapy for breast cancer in the United Kingdom.
De Cock E; Hutton J; Canney P; Body JJ; Barrett-Lee P; Neary MP; Lewis G
Clin Ther; 2005 Aug; 27(8):1295-310. PubMed ID: 16199254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
